Systematic literature review assessing the overall costs and societal impacts of moderate-to-severe atopic dermatitis in Europe.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
11
03
2022
accepted:
11
07
2022
pubmed:
4
8
2022
medline:
16
11
2022
entrez:
3
8
2022
Statut:
ppublish
Résumé
Atopic dermatitis (AD) is a chronic inflammatory disease, driven by type 2 inflammation. The condition manifests as moderate-to-severe disease in approximately 20% of adults with AD across Europe and is associated with a substantial burden on patients, society and healthcare systems. However, systematic assessments capturing the totality of disease burden associated with moderate-to-severe AD are limited; therefore, the overall impacts of the disease may be underestimated. A systematic literature review (SLR) was carried out to assess the overall costs of moderate-to-severe AD across Europe, including the financial, societal and humanistic impacts. PubMed, Embase and Cochrane databases were searched to identify relevant studies published between 1 January 2010 and 2 June 2020. Scientific conference proceedings, health technology assessment websites and patient association group websites were also searched for relevant information. Twenty-seven publications, corresponding to 22 unique studies, were included in the analysis. Total costs (direct and productivity losses) reached €20 695 per-person-per-year (PPPY) for adults with uncontrolled symptoms of moderate-to-severe AD. Direct medical costs ranged between €307 and €6993 PPPY; prescription medications and specialist dermatologist visits were the main contributors. Costs increased with disease severity or with uncontrolled disease. Patients with AD also incurred personal costs of €927 per year for healthcare items not reimbursed, which increased by 9% for those with moderate-to-severe forms. Annual work productivity losses comprised most of the total costs reported for adults with moderate-to-severe AD (up to 60.8% of the total burden) and were highest in those with uncontrolled disease (€13 702 PPPY). Patients with moderate-to-severe disease also experienced physical, emotional, and social impacts. The overall costs of moderate-to-severe AD greatly impact on healthcare systems, patients and society. Sustained control of moderate-to-severe AD, through effective treatment and care management, is essential to limit the burden caused by the disease.
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2316-2324Subventions
Organisme : Sanofi
Informations de copyright
© 2022 European Academy of Dermatology and Venereology.
Références
Bieber T. Atopic Dermatitis. Ann Dermatol 2010; 22: 125-137.
Boguniewicz M, Leung DYM. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011; 242: 233-246.
Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis--part I: clinical and pathologic concepts. J Allergy Clin Immunol 2011; 127: 1110-1118.
Silverberg JI, Barbarot S, Gadkari A et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol 2021; 126: 417-428 e412.
Barbarot S, Auziere S, Gadkari A et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy 2018; 73: 1284-1293.
Augustin M, Radtke MA, Glaeske G et al. Epidemiology and comorbidity in children with psoriasis and atopic eczema. Dermatology 2015; 231: 35-40.
Deleanu D, Nedelea I. Biological therapies for atopic dermatitis: an update. Exp Ther Med 2019; 17: 1061-1067.
National Eczema Association. Atopic Dermatitis. Available from: https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis/. Last accessed 1 June 2021.
Brown SJ. Atopic eczema. Clin Med (Lond) 2016; 16: 66-69.
Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387: 1109-1122.
Dalgard FJ, Gieler U, Tomas-Aragones L et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol 2015; 135: 984-991.
Eckert L, Gupta S, Gadkari A, Mahajan P, Gelfand JM. Burden of illness in adults with atopic dermatitis: analysis of National Health and wellness survey data from France, Germany, Italy, Spain, and the United Kingdom. J Am Acad Dermatol 2019; 81: 187-195.
Misery L, Seneschal J, Reguiai Z et al. The impact of atopic dermatitis on sexual health. J Eur Acad Dermatol Venereol 2019; 33: 428-432.
Misery L, Seneschal J, Reguiai Z et al. Patient burden is associated with alterations in quality of life in adult patients with atopic dermatitis: results from the ECLA study. Acta Derm Venereol 2018; 98: 713-714.
Ariens LFM, van Nimwegen KJM, Shams M et al. Economic burden of adult patients with moderate to severe atopic dermatitis indicated for systemic treatment. Acta Derm Venereol 2019; 99: 762-768.
Sicras-Mainar A, Navarro-Artieda R, Carrascosa Carrillo JM. Economic impact of atopic dermatitis in adults: a population-based study (IDEA study). Actas Dermosifiliogr 2018; 109: 35-46.
Sciattella P, Pellacani G, Pigatto PD et al. The burden of atopic dermatitis in adults in Italy. G Ital Dermatol Venereol 2020; 155: 19-23.
Arents BWM, Mensing U, Seitz IA et al. Atopic eczema score of emotional consequences-a questionnaire to assess emotional consequences of atopic eczema. Allergo J Int 2019; 28: 277-288.
Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M. Psoriasis: is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol 2010; 24: 989-1004.
Wollenberg A, Christen-Zäch S, Taieb A et al. ETFAD/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020; 34: 2717-2744.
Yum HY, Kim HH, Kim HJ et al. Current Management of Moderate-to-Severe Atopic Dermatitis: a survey of allergists, pediatric allergists and dermatologists in Korea. Allergy Asthma Immunol Res 2018; 10: 253-259.
Augustin M. Cumulative life course impairment: identifying patients at risk. Curr Probl Dermatol 2013; 44: 74-81.
Augustin M, Langenbruch A, Blome C et al. Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation. J Eur Acad Dermatol Venereol 2020; 34: 142-152.
Plant A, Ardern-Jones MR. Advances in atopic dermatitis. Clin Med (Lond) 2021; 21: 177-181.
Gisondi P, Girolomoni G. Undertreatment in adult patients with moderate-to-severe atopic dermatitis and other chronic inflammatory skin diseases. J Eur Acad Dermatol Venereol 2020; 34: 2168-2169.
Pascal C, Maucort-Boulch D, Gilibert S et al. Therapeutic management of adults with atopic dermatitis: comparison with psoriasis and chronic urticaria. J Eur Acad Dermatol Venereol 2020; 34: 2339-2345.
Organisation for Economic Co-operation and Development (OECD). Healthcare costs unsustainable in advanced economies without reform. Available from: http://www.oecd.org/health/healthcarecostsunsustainableinadvancedeconomieswithoutreform.htm. Last accessed 22 September 2020.
Chung J, Simpson EL. The socioeconomics of atopic dermatitis. Ann Allergy Asthma Immunol 2019; 122: 360-366.
Nørreslet LB, Ebbehøj NE, Ellekilde Bonde JP, Thomsen SF, Agner T. The impact of atopic dermatitis on work life - a systematic review. J Eur Acad Dermatol Venereol 2018; 32: 23-38.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-1012.
Theodosiou G, Montgomery S, Metsini A, Dalgard FJ, Svensson Å, Kobyletzki LB. Burden of atopic dermatitis in Swedish adults: a population-based study. Acta Derm Venereol 2019; 99: 964-970.
Thyssen JP, Hamann CR, Linneberg A et al. Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide. Allergy 2018; 73: 214-220.
Thomas KS, Koller K, Dean T et al. A multicentre randomised controlled trial and economic evaluation of ion-exchange water softeners for the treatment of eczema in children: the softened water eczema trial (SWET). Health Technol Assess 2011; 15;v-vi: 1-156.
Schuttelaar ML, Vermeulen KM, Coenraads PJ. Costs and cost-effectiveness analysis of treatment in children with eczema by nurse practitioner vs. dermatologist: results of a randomized, controlled trial and a review of international costs. Br J Dermatol 2011; 165: 600-611.
Thaci D, Chambers C, Sidhu M, Dorsch B, Ehlken B, Fuchs S. Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months. J Eur Acad Dermatol Venereol 2010; 24: 1040-1046.
Launois R, Ezzedine K, Cabout E et al. Importance of out-of-pocket costs for adult patients with atopic dermatitis in France. J Eur Acad Dermatol Venereol 2019; 33: 1921-1927.
Zink AGS, Arents B, Fink-Wagner A et al. Out-of-pocket costs for individuals with atopic eczema: a cross-sectional study in nine European countries. Acta Derm Venereol 2019; 99: 263-267.
Andersen L, Nyeland ME, Nyberg F. Increasing severity of atopic dermatitis is associated with a negative impact on work productivity among adults with atopic dermatitis in France, Germany, the U.K. and the U.S.A. Br J Dermatol 2020; 182: 1007-1016.
Torrelo A, Ortiz J, Alomar A, Ros S, Prieto M, Cuervo J. Atopic dermatitis: impact on quality of life and patients' attitudes toward its management. Eur J Dermatol 2012; 22: 97-105.
Pinheiro B, Gouveia M, Borges M. PSY6 absenteeism in adult patients with moderate-to-severe treated atopic dermatitis in Portugal: an econometric analysis. Value Health 2019; 22: S902.
Haufe E, Abraham S, Heratizadeh A et al. Decreased professional performance and quality of life in patients with moderate-to-severe atopic eczema: results from the German atopic eczema registry TREATgermany. Hautarzt 2018; 69: 815-824.
Slagor RM, Nørreslet LB, Ebbehøj NE, Bonde JP, Thomsen SF, Agner T. Atopic dermatitis is associated with increased use of social benefits: a register-based cohort study. J Eur Acad Dermatol Venereol 2020; 34: 549-557.
Schonmann Y, Mansfield KE, Hayes JF et al. Atopic eczema in adulthood and risk of depression and anxiety: a population-based cohort study. J Allergy Clin Immunol Pract 2020; 8: 248-257.e216.
Egeberg A, Griffiths CEM, Williams HC, Andersen YMF, Thyssen JP. Clinical characteristics, symptoms and burden of psoriasis and atopic dermatitis in adults. Br J Dermatol 2020; 183: 128-138.
Ring J, Zink A, Arents BWM et al. Atopic eczema: burden of disease and individual suffering - results from a large EU study in adults. J Eur Acad Dermatol Venereol 2019; 33: 1331-1340.
Sánchez-Pérez J, Daudén-Tello E, Mora AM, Lara SN. Impact of atopic dermatitis on health-related quality of life in Spanish children and adults: the PSEDA study. Actas Dermosifiliogr 2013; 104: 44-52.
Boccardi D, D'Auria E, Turati F et al. Disease severity and quality of life in children with atopic dermatitis: PO-SCORAD in clinical practice. Minerva Pediatr 2017; 69: 373-380.
Ražnatović Djurović M, Janković J, Tomić Spirić V, Janković S. Health-related quality of life in children with moderate to severe atopic dermatitis. Acta Dermatovenerol Croat 2015; 23: 178-184.
Ridolo E, Caffarelli C, Olivieri E et al. Quality of sleep in allergic children and their parents. Allergol Immunopathol (Madr) 2015; 43: 180-184.
Monti F, Agostini F, Gobbi F, Neri E, Schianchi S, Arcangeli F. Quality of life measures in Italian children with atopic dermatitis and their families. Ital J Pediatr 2011; 37: 59.
Kullavanijaya P. More than just eczema. Lancet 2000; 356(Suppl): s59.
Mattei PL, Corey KC, Kimball AB. Cumulative life course impairment: evidence for psoriasis. Curr Probl Dermatol 2013; 44: 82-90.
Augustin M, Alvaro-Gracia JM, Bagot M et al. A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol 2012; 26(Suppl 4): 1-16.
Ring J, Bachert C, Bauer C, Czech W. White Paper Allergy in Germany 3rd Edition [Weißbuch Allergie in Deutschland 3 Auflage]. Munich, Springer Medizin, 2010.
Jungen D, Augustin M, Langenbruch A et al. Cost-of-illness of psoriasis - results of a German cross-sectional study. J Eur Acad Dermatol Venereol 2018; 32: 174-180.
Mohr N, Naatz M, Zeervi L et al. Cost-of-illness of atopic dermatitis in Germany: data from dermatology routine care. J Eur Acad Dermatol Venereol 2021; 35: 1346-1356.
Kaaz K, Szepietowski JC, Matusiak Ł. Influence of itch and pain on sleep quality in atopic dermatitis and psoriasis. Acta Derm Venereol 2019; 99: 175-180.
Langenbruch A, Radtke M, Franzke N, Ring J, Foelster-Holst R, Augustin M. Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth. J Eur Acad Dermatol Venereol 2014; 28: 719-726.
Taieb C, Ezzedine K, Reguiai Z, Misery L, Seneschal J. The burden of AD in French adult patients: a multicentric cross-sectional study. Value Health 2017; 20: A943.
Misery L, Seneschal J, Ezzedine K et al. Atopic dermatitis is associated with poor quality of life in adult patients. Value Health 2017; 20: A808.